Articles related to All Specialties

Let’s delve into the complexity of mask effectiveness against SARS-CoV-2 in diverse settings. Debate rages on about optimal mask use for COVID-19 prevention. This trial takes a fresh look at the issue. It evaluates N95, surgical, and cloth masks in preventing SARS-CoV-2 infections. The team sourced data from MEDLINE, EMBASE, and medRxiv. They also scanned relevant reference lists. They selected randomized trials and observational studies. These studies increased mask use and controlled for confounding factors in assessing SARS-CoV-2 infection risk. Two investigators carried out the data extraction process. They carefully abstracted data from each study and evaluated its quality. Their efforts resulted in the inclusion of three randomized trials and 21 observational studies. Evidence from two trials and seven studies points to a possible reduction in SARS-CoV-2 infection risk through mask use in community settings. Despite this, observational studies failed to provide sufficient evidence for other mask comparisons due to methodological inconsistencies. In routine patient care settings, one new trial and four studies indicated comparable infection risk between surgical masks and N95 respirators. However, the study couldn’t disregard the potential beneficial effects of N95 respirators. Yet, several limitations cloud these findings. These include a limited number of randomized trials, methodological […]

Dive into the potential of senolytics in combating age-related diseases, revealing how these compounds might unlock a healthier, longer life. Although senescent cells play crucial roles in early life, their persistence in later years can link to numerous age-related diseases. The potential of senolytics, such as dasatinib and quercetin (D&Q), is being explored in clearing out these harmful cells and combating age-related diseases like cancer, diabetes, and osteoporosis. To illustrate, researchers applied D&Q as senolytics in patients with idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease. Findings revealed that patients showed improvements in physical function, with benefits including enhanced gait speed and increased walking distance. Similarly, the treatment significantly reduced cellular senescence in another study involving patients with diabetic kidney disease. However, caution is advised. Experts insist on the need for additional long-term studies and human clinical trials to confirm the safety of these senolytics. The majority of global morbidity, mortality, and health costs stem from chronic illnesses. Age, as indicated by JAMA, is a significant predictive factor for most of these diseases. Therefore, research aiming to “turn back the clock” and mitigate the effects of aging is well underway. Among the promising strategies is the removal of senescent cells, […]

The FDA’s controversial approval of Recarbrio in 2019 marked a deviation from the expected standards of drug effectiveness. Before 1962, US drug approvals didn’t require pre-market proof of effectiveness. Following Senate hearings and the Thalidomide disaster, however, the law changed. Nowadays, FDA approval for new drugs requires substantial evidence of effectiveness from well-controlled investigations. Strikingly, a National Academy of Sciences review found over 30% of pre-1962 drugs to be ineffective, highlighting the importance of these regulations. FDA’s regulations provide a detailed explanation of what constitutes substantial evidence. Though not perfect, these regulations reassure prescribers, patients, and payers of the scientific basis of drug efficacy claims. It’s important to note that an FDA review found 59% of rejected NDAs had deficiencies in efficacy evidence. Nevertheless, the FDA’s controversial approval of Recarbrio in 2019 raised eyebrows. This drug, a combination of imipenem, cilastatin, and relebactam, was approved despite lacking substantial evidence of effectiveness and proper clinical investigations. Disturbingly, FDA officials cited animal and laboratory studies as substantial evidence, a move contrary to legal and regulatory norms. Moreover, the Recarbrio approval showcased other troubling departures from regulatory principles. The FDA failed to require proof of each active component’s contribution to the claimed effect. […]

Physician burnout: A rising concern in the medical field, driving doctors to explore alternative career paths. Physician burnout has reached an alarming stage, with doctors increasingly contemplating leaving their medical practices. This exodus has primarily been influenced by the intense stress, emotional trauma, and overwhelming challenges they face in their careers. Importantly, the trend is not just an individual crisis, but a looming threat to the healthcare system. According to recent studies, 20% of physicians express intentions to quit their current practice within two years, and a third aim to cut down their working hours significantly. These statistics could precipitate a healthcare crisis, with the Association of American Medical Colleges predicting a potential shortage of 37,800 to 124,000 physicians by 2034. It’s worth noting that the reasons for this growing disenchantment extend beyond the physical and mental toll of the COVID-19 pandemic. Instead, doctors attribute their dissatisfaction to various issues tied to the broader healthcare landscape. They report frequent clashes with insurance companies, dwindling physician autonomy, bureaucratic hurdles, hostility from patients, lack of support from hospital administrations, and an inability to practice the art of bedside medicine. Physicians are not walking away from their professions because they can’t handle the […]

Navigate the rapidly changing landscape of patient communication, as we explore the ins and outs of charging for MyChart messages. The COVID-19 pandemic has swiftly transformed the dynamics of healthcare communication. Consequently, healthcare providers increasingly rely on telehealth visits and digital communication tools to connect with patients. A significant offshoot of this shift is the growing trend of charging for MyChart messages. Healthcare systems have begun charging for the time providers spend responding to messages. Some hospitals have even expressed plans to bill up to $50 for MyChart messages. This new approach was permitted through changes to the 2020 Current Procedural Terminology (CPT) codes. The revised codes introduced three new time-based categories, thereby allowing providers to bill for time spent addressing patient-initiated messages over a week. Despite these changes, not all services come with a price tag. As per the Cleveland Clinic, any work taking under five minutes or any service that leads to an in-person consultation will not be charged. Furthermore, no fees apply to prescription refill requests, appointment requests, and follow-up care related to a surgery performed within the last 90 days. However, specific services can be billed. For instance, messages necessitating a clinical assessment, ordering a test […]

The case involves a 73-year-old patient, Ms. B, who had a history of rheumatoid arthritis and was taking prednisone for adrenal insufficiency caused by a pituitary tumor. She was treated by an internist, Dr. R, for various ailments over a period of four years. In November 2016, Ms. B was diagnosed with severe community-acquired pneumonia and admitted to the hospital, where she was treated with levofloxacin. After being discharged, she continued taking levofloxacin and suffered an acute rupture of the gluteus medius tendon, resulting in significant disabilities. Ms. B filed a lawsuit against Dr. R, alleging negligence and failure to inform her about the risks and contraindications of the medication. Dr. R sought a summary judgment to have the case dismissed but was denied by the court. The court ruled that a Boxed Warning on a medication, such as the one associated with levofloxacin, can create a triable issue of fact regarding a physician’s departure from accepted medical practice. Dr. R claimed he was unaware of the risks and relied on the hospitalists’ choice of medication, but the court found that he should have been knowledgeable about the specific risks and suitability of the medication for his patient. The case […]